Relvar

Type: Product
Name: Relvar
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Theravance to Report Second Quarter 2014 Financial Results on August 6, 2014

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/29/14 -- Theravance, Inc. ( NASDAQ: THRX ) announced today that it will release financial results for the period ended June 30, 2014 after market close on Wednesday, August 6, 2014.An accompanying conference ... [Published CEOWorld Magazine - Jul 29 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 1 reports

UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

In a report published Thursday, Bank of America analyst Steve Byrne downgraded the rating on Theravance (NASDAQ: THRX) from Buy to Neutral, and lowered the price target from $34.00 to $31.00.In the report, Bank of America noted, “Following comments from ... [Published Benzinga.com - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 5 reports

Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

/PRNewswire/ -- finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid ... [Published Freshnews.com - Jul 24 2014]
Entities: Relvar, Asthma, Experience
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

GlaxoSmithKline in free-fall

Down 6%, the drug giant's share price has plunged through technical support at around 1,540p to its lowest since early 2013. And while the prospective dividend yield of 5% looks attractive, growth prospects look anaemic.A strong pound is certainly no ... [Published Interactive Investor - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Theravance : GSK and Theravance Introduce Initiation of Phase III Programme

GlaxoSmithKline plc and Theravance, Inc. reported the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COP ... [Published 4 Traders - Jul 22 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

GlaxoSmithKline and Theravance begin new COPD drug trial

:21 in Pharmaceutical Company Product News GlaxoSmithKline and Theravance have allied to trial a new chronic obstructive pulmonary disease (COPD) drug in a global phase III study called Impact. Involving approximately 10,000 patients, the study will assess ... [Published Zenopa - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 5 reports

Theravance/Glaxo Commence Global Late stage Study on COPD

Theravance, Inc. ( THRX ) and partner GlaxoSmithKline ( GSK ) announced the commencement of a phase III study (IMPACT: n=10,000) to evaluate the safety and efficacy of a triple combination treatment in patients suffering from chronic obstructive pulmonary ... [Published Yahoo! Finance - Jul 16 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

THERAVANCE : Selects Theodore J. Witek, Jr. as Senior VP of Corporate Partnerships, Clinical and Medical Affairs

Theravance, Inc. reported the appointment of Theodore J. Witek , Jr. as Senior Vice President Corporate Partnerships, Clinical and Medical Affairs.According to a release, Dr. Witek will report directly to Rick E Winningham, Chief Executive Officer and ... [Published 4 Traders - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Glaxo/Theravance Drug Gets Japanese Approval

GlaxoSmithKline ( GSK - Analyst Report ) and partner Theravance ( THRX - Analyst Report ) announced that their respiratory drug, Anoro Ellipta (once daily), has been cleared by the Japanese Ministry of Health, Labour and Welfare (MHLW). The approval ... [Published Zacks.com - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

SKYEPHARMA : announces Full Year 2013 Results

Financial Highlights- Revenues up 25% per cent. to £62.6m (2012: £49.9m), primarily due to growth in flutiform® supply, increased contract development, and the Group's share of higher net sales of Pacira's EXPAREL®- Pre-exceptional operating profit up ... [Published 4 Traders - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 03 2014 - 2 reports

Theravance, Inc. Appoints Theodore J. Witek, Jr. as Senior Vice President, Corporate Partnerships, Clinical and Medical Affairs

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/02/14 -- Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical and ... [Published Stock Nod - Jul 02 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 2 reports

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

US pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) have submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for a fixed dose combination of the inhaled corticosteroid, fluticasone ... [Published Pharma Letter - Jul 01 2014]

Quotes

...efficacy profile in asthma indication, Relvar's pricing will be key for its favorable placement in the treatment guideline and for driving uptake. "Even though payers across the EU5 have only a modest cost-saving expectation for generic LABA/ICS FDCs and for biosimilar omalizumab, they indicate a strong interest in promoting the usage of these agents, particularly for treatment-naive patients. However, they are less enthusiastic for biosimilar omalizumab, likely due to the lack of experience with biosimilars to date which contributes to payer and physician uncertainty regarding biosimilar omalizumab's safety and bioequivalency to Xolair. This could be mitigated by biosimilar omalizumab demonstrating a robust safety and bioequivalency profile compared to Xolair."
"Although sales of flagship drug Advair were broadly in-line, the two new respiratory drugs, Breo/Relvar and Anoro, undershot our seemingly-conservative expectations and only the new HIV drug Tivicay is performing ahead of forecasts" explains Deutsche Bank
Rick E Winningham, Chief Executive Officer of Theravance , said: "The start of the IMPACT study marks a significant milestone in our development programme with GSK and we are excited about the potential opportunity for a triple combination treatment approach. This phase III programme has the potential to demonstrate the safety and efficacy profile of a new and important therapy that could deliver additional benefits and convenience to the growing number of adults living with COPD worldwide."
...Dave Allen, head of respiratory therapy research and development at GlaxoSmithKline, said: "The Impact study will be important in advancing our understanding of how the combination of FF/UMEC/VI could be used in this setting when compared to dual combination therapy options." This comes after the companies received approval for the European launch of Anoro in May this year

More Content

All (54) | News (47) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Theravance to Report Second Quarter 2014 Financ... [Published CEOWorld Magazine - Jul 29 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published Freshnews.com - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect That Relvar,... [Published TheStreet.com - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published Securities Technology Monitor - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published RCL Advisors - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
Theravance Downgraded to Neutral at Morgan Stan... [Published American Banking News - Stock Ratings - Jul 24 2014]
UPDATE: Bank Of America Downgrades Theravance A... [Published Benzinga.com - Jul 24 2014]
GlaxoSmithKline in free-fall [Published Interactive Investor - Jul 23 2014]
Theravance : GSK and Theravance Introduce Initi... [Published 4 Traders - Jul 22 2014]
GlaxoSmithKline and Theravance begin new COPD d... [Published Zenopa - Jul 17 2014]
Theravance/Glaxo Commence Global Late stage Stu... [Published Yahoo! Finance - Jul 16 2014]
GSK and Theravance Initiate Phase III Program f... [Published PharmaceuticalProcessing - Jul 16 2014]
GSK and Theravance initiate global Phase III st... [Published Pharma Letter - Jul 16 2014]
GSK trial throws everything at COPD [Published PMLive - Jul 16 2014]
GSK share price: Group starts late-stage trial ... [Published Invezz - Jul 16 2014]
GSK and Theravance put triple COPD combo into P... [Published Pharma Times - Jul 16 2014]
GSK and Theravance start phase III study [Published Stock Market Wire - Jul 16 2014]
Start of phase III study - FF/UMEC/VI combination [Published Noodls - Jul 16 2014]
GlaxoSmithKline, Theravance Initiate Phase III ... [Published 4 Traders - Jul 16 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published 4 Traders - Jul 10 2014]
Anoro® Ellipta® approved in Australia for Chron... [Published Noodls - Jul 09 2014]
THERAVANCE : Selects Theodore J. Witek, Jr. as ... [Published 4 Traders - Jul 08 2014]
Glaxo/Theravance Drug Gets Japanese Approval [Published Zacks.com - Jul 07 2014]
Theravance appoints SVP of corporate partnershi... [Published Individual.com - Jul 07 2014]
SKYEPHARMA : announces Full Year 2013 Results [Published 4 Traders - Jul 03 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Yahoo! Finance - Jul 02 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Benzinga.com - Jul 02 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Stock Nod - Jul 02 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ...
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ...
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnerships, Commercial. ...
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ...
Patient Recruitment Completes in Landmark RELVA... [Published Marketwire - Breaking News Releases - Mar 13 2014]
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 13, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that recruitment of patients into the "Study to Understand Mortality and ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.